HCN Oncology Year-in-Review: CRCDecember 21, 2021 | Oncology Gastroenterology Mortality Risk Increased for MS Patients Soon After CRC Diagnosis According to a study published online in Neurology, in the 6 months after a colorectal cancer (CRC) diagnosis, patients with multiple sclerosis (MS) have an increased risk of all-cause and cancer-specific death. Data were included for 338 MS cases and 1,352 controls without MS, matched for birth year, sex, cancer diagnosis year, and region. Read full article Gastroenterology Cases in the Management of Metastatic CRC: Regorafenib as 2L Therapy After FOLFOXIRI + Bevacizumab in a Patient With a KRAS Mutation The case reported is based on a 53-year-old woman who presented to her gastroenterologist with symptoms of bowel obstruction and right upper quadrant pain. Based on her age and excellent performance status, aggressive treatment with a triplet chemotherapy regimen of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFOXIRI) in combination with the anti–vascular endothelial growth factor receptor antibody bevacizumab was begun. Read full article Gastroenterology Considerations in the Management of Younger Patients With Colorectal Cancer It is important for young people, caregivers, and healthcare providers to recognize possible symptoms of colorectal cancer (CRC) and arrange a colonoscopy or other tests when necessary. This article presents a thorough review of CRC and its impact on young patients, including a hypothesis for the increase of cases, screening recommendations, demographic features, symptoms, and recommendations for physicians. Read full article Gastroenterology Family History of CCIS Linked to Increased Risk of Invasive Colorectal Cancer Using data from Swedish family cancer datasets to calculate standardized incidence ratios (SIRs) and the cumulative risk of invasive colorectal cancer (CRC) in first- and second-degree relatives of people with colorectal carcinoma in situ (CCIS) or invasive CRC, the Journal of the National Comprehensive Cancer Network (JNCCN) suggests that family history of CCIS should be considered similarly to family history of invasive CRC in risk stratification for earlier CRC screening. Read full article Gastroenterology KRAS G12C Mutations in Metastatic Colorectal Cancer: Questions Remain Studies suggest that G12C mutations occur in 3% to 8% of total colorectal cancer (CRC) cases and constitute 6% to 17% of KRAS mutations. Having a G12C mutation may be an adverse prognostic factor in mCRC, but confounding factors may be more responsible for differences in treatment outcomes than the G12C mutation itself. The two conflicting presentations at the ESMO World Congress on Gastrointestinal Cancer highlight the critical need to define the prognostic significance of the G12C mutation and the resulting treatment implications more precisely. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS